NASDAQ:GNFTGENFIT S A/ADR Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GENFIT S A/ADR Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.22 -0.03 (-0.57 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$5.21Now: $5.22▼$5.3750-Day Range$5.25MA: $16.35▼$22.0052-Week Range$5.21Now: $5.22▼$24.85Volume286,890 shsAverage Volume258,350 shsMarket Capitalization$197.47 millionP/E RatioN/ADividend YieldN/ABeta1.29 ProfileAnalyst RatingsAdvanced ChartCompetitorsInstitutional OwnershipHeadlinesSocial Media Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.Read More Beat the Market (BTM) Rank™ 4.1 Analyst's Opinion Consensus RatingGENFIT S A/ADR has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 3 buy ratings, 4 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.75, GENFIT S A/ADR has a potential upside of 948.9% from its current price of $5.22.Amount of Analyst CoverageGENFIT S A/ADR has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.8 Community Rank Outperform VotesGENFIT S A/ADR has received 43 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGENFIT S A/ADR has received 35 “underperform” votes. (Add your “underperform” vote.)Community SentimentGENFIT S A/ADR has received 55.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about GENFIT S A/ADR and other stocks. Vote “Outperform” if you believe GNFT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNFT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGENFIT S A/ADR does not currently pay a dividend.Dividend GrowthGENFIT S A/ADR does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GENFIT S A/ADR insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 2.94% of the stock of GENFIT S A/ADR is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for GENFIT S A/ADR are expected to grow in the coming year, from ($2.21) to ($1.92) per share.Price to Book Value per Share RatioGENFIT S A/ADR has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.1Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNFT Previous Symbol CUSIPN/A CIKN/A Webwww.genfit.com Phone33-3-20-16-40-00Debt Debt-to-Equity Ratio2.13 Current Ratio6.68 Quick Ratio6.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$45.88 million Price / Sales4.30 Cash FlowN/A Price / Cash FlowN/A Book Value$2.49 per share Price / Book2.10Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees148 Outstanding Shares37,830,000Market Cap$197.47 million Next Earnings DateN/A OptionableNot Optionable NASDAQ:GNFT Rates by TradingView Receive GNFT News and Ratings via Email Sign-up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. GENFIT S A/ADR (NASDAQ:GNFT) Frequently Asked Questions How has GENFIT S A/ADR's stock been impacted by COVID-19 (Coronavirus)? GENFIT S A/ADR's stock was trading at $14.23 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GNFT shares have decreased by 63.3% and is now trading at $5.22. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of GENFIT S A/ADR? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GENFIT S A/ADR in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for GENFIT S A/ADR. What price target have analysts set for GNFT? 9 equities research analysts have issued twelve-month price objectives for GENFIT S A/ADR's stock. Their forecasts range from $11.00 to $174.00. On average, they expect GENFIT S A/ADR's share price to reach $54.75 in the next year. This suggests a possible upside of 948.9% from the stock's current price. View analysts' price targets for GENFIT S A/ADR. Has GENFIT S A/ADR been receiving favorable news coverage? News stories about GNFT stock have been trending very positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GENFIT S A/ADR earned a news impact score of 4.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutGENFIT S A/ADR. Who are some of GENFIT S A/ADR's key competitors? Some companies that are related to GENFIT S A/ADR include BAVARIAN NORDIC/S (BVNRY), Replimune Group (REPL), Adaptimmune Therapeutics (ADAP), Aerie Pharmaceuticals (AERI), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Vericel (VCEL), AVITA MED LTD/S (RCEL), Avrobio (AVRO), Prevail Therapeutics (PRVL), Oyster Point Pharma (OYST), Aptose Biosciences (APTO), MeiraGTx (MGTX), Harpoon Therapeutics (HARP) and Innate Pharma (IPHYF). View all competitors. What other stocks do shareholders of GENFIT S A/ADR own? Based on aggregate information from My MarketBeat watchlists, some companies that other GENFIT S A/ADR investors own include Intercept Pharmaceuticals (ICPT), InterDigital Wireless (IDCC), Stag Industrial (STAG), Amarin (AMRN), Gilead Sciences (GILD), Zynerba Pharmaceuticals (ZYNE), Vaxart (VXRT), Agile Therapeutics (AGRX), Aimmune Therapeutics (AIMT) and Advanced Micro Devices (AMD). Who are GENFIT S A/ADR's key executives? GENFIT S A/ADR's management team includes the following people: Mr. Jean-François Mouney, Co-Founder, CEO & Chairman (Age 64)Ms. Nathalie Huitorel, Exec. VP, Chief Financial & Admin. Officer (Age 58)Dr. Dean W. Hum, Chief Operating Officer (Age 57)Prof. Bart Staels, Co-Founder & Pres of the Scientific Advisory Board (Age 56)Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 49) When did GENFIT S A/ADR IPO? (GNFT) raised $132 million in an initial public offering on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays served as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers. What is GENFIT S A/ADR's stock symbol? GENFIT S A/ADR trades on the NASDAQ under the ticker symbol "GNFT." Who are GENFIT S A/ADR's major shareholders? GENFIT S A/ADR's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.64%), Aperio Group LLC (0.06%) and Morgan Stanley (0.03%). Which major investors are selling GENFIT S A/ADR stock? GNFT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. Which major investors are buying GENFIT S A/ADR stock? GNFT stock was acquired by a variety of institutional investors in the last quarter, including Aperio Group LLC, and Morgan Stanley. How do I buy shares of GENFIT S A/ADR? Shares of GNFT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is GENFIT S A/ADR's stock price today? One share of GNFT stock can currently be purchased for approximately $5.22. How big of a company is GENFIT S A/ADR? GENFIT S A/ADR has a market capitalization of $197.47 million and generates $45.88 million in revenue each year. GENFIT S A/ADR employs 148 workers across the globe. What is GENFIT S A/ADR's official website? The official website for GENFIT S A/ADR is www.genfit.com. How can I contact GENFIT S A/ADR? GENFIT S A/ADR's mailing address is PARC EURASANTE 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The company can be reached via phone at 33-3-20-16-40-00 or via email at [email protected] This page was last updated on 5/25/2020 by MarketBeat.com Staff
